19 June 2013
Keywords: topotarget, says, failed, aguvane, study, worthwhile, although
Article | 30 March 2009
Although Danish firm TopoTarget's Avugane gel (valproic acid) failed to reach significance in a Phase II trial comparing three doses ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
There are no related articles.
18 June 2013
© 2013 thepharmaletter.com